key: cord-0683054-41nllx7j
authors: Starr, Tyler N.; Greaney, Allison J.; Hannon, William W.; Loes, Andrea N.; Hauser, Kevin; Dillen, Josh R.; Ferri, Elena; Farrell, Ariana Ghez; Dadonaite, Bernadeta; McCallum, Matthew; Matreyek, Kenneth A.; Corti, Davide; Veesler, David; Snell, Gyorgy; Bloom, Jesse D.
title: Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
date: 2022-02-26
journal: bioRxiv
DOI: 10.1101/2022.02.24.481899
sha: 9b715f5c6a5efe9ecd050303485d345ae1eaedce
doc_id: 683054
cord_uid: 41nllx7j

SARS-CoV-2 has evolved variants with substitutions in the spike receptor-binding domain (RBD) that impact its affinity for ACE2 receptor and recognition by antibodies. These substitutions could also shape future evolution by modulating the effects of mutations at other sites—a phenomenon called epistasis. To investigate this possibility, we performed deep mutational scans to measure the effects on ACE2 binding of all single amino-acid mutations in the Wuhan-Hu-1, Alpha, Beta, Delta, and Eta variant RBDs. Some substitutions, most prominently N501Y, cause epistatic shifts in the effects of mutations at other sites, thereby shaping subsequent evolutionary change. These epistatic shifts occur despite high conservation of the overall RBD structure. Our data shed light on RBD sequence-function relationships and facilitate interpretation of ongoing SARS-CoV-2 evolution.

The impact on ACE2 receptor-binding affinity (Δlog10(KD)) of every single amino-acid mutation in SARS-CoV-2 RBDs, as determined by high-throughput titration assays (Fig. S1 ). The wildtype amino acid in each variant is indicated with an "x", and gray squares indicate missing mutations in each library. An interactive version of this map is at https://jbloomlab.github.io/SARS-CoV-2-RBD_DMS_variants/RBD-heatmaps/, and raw data are in Data S1. The effects of mutations on RBD surface expression are in Fig. S2 . binding affinity. The Q498R/N501Y double mutation was first discovered in directed evolution studies (6) and is present in the RBD of the Omicron BA.1 and BA.2 variants (8) . The epistasis between these two mutations is crucial for enabling the Omicron RBD to bind ACE2 with high affinity despite having a large number of mutations (10) (11) (12) . Specifically, the set of mutations in the Omicron RBD are predicted to strongly impair ACE2 affinity based on their summed single-mutant effects in Wuhan-Hu-1 (Fig. 3B, left panel) , but their summed single-mutant effects in the Beta background (which has N501Y) is about zero, consistent with the actual affinity of the Omicron RBD for ACE2 (Fig.  3B, right panel) . Therefore, the affinity buffer conferred by the epistatic Q498R/N501Y pair enables the Omicron spike to tolerate other mutations that are deleterious for ACE2 binding (Fig. 3B and Fig. S5A ) but contribute to antibody escape (Fig. S5B ,C) (9) . Consistent with these affinity measurements, introducing R498Q and Y501N reversions into the Omicron BA.1 spike reduces cell entry by spike-pseudotyped lentiviral particles, demonstrating that the remaining Omicron RBD mutations are deleterious without buffering by Q498R/N501Y ( Fig. 3C and Fig. S6A,B) .

There is also evolutionary relevance of the epistasis of N501Y with mutations on the 446-449 loop, which comprises the epitope for an important class of human antibodies (13, 14) . Although mutations to G446 escape this class of antibodies in the Wuhan-Hu-1 RBD (14, 15) , these mutations incur a strong ACE2-binding deficit in the N501Y background (Figs. S3B and S5D). Conversely, mutations to Y449 are largely deleterious in the Wuhan-Hu-1 RBD but are better tolerated when accompanied by N501Y (Figs. 2C, 3D). Mutations to Y449 can escape monoclonal antibodies ( Fig. S6C -E) (13, 16) and reduce neutralization by polyclonal sera (17, 18) . Mutations to Y449 have been described in several variants that also contain N501Y, including the C.1.2, A.29, and B.1.640 lineages (17, 19) .

To more systematically examine how epistatic shifts impact patterns of sequence variation during SARS-CoV-2 evolution, we counted the occurrence of substitutions on a global SARS-CoV-2 phylogeny (20) . We observed that mutations more often occurred in backgrounds containing the amino acid at site 501 with which they had more favorable epistasis (Fig. 3E) . Therefore, our data enables identification of mutations like those at site Y449 whose evolutionary relevance may grow if N501Y variants continue to predominate.

However, other common combinations of mutations are not involved in specific epistatic interactions with respect to ACE2 affinity. For instance, substitutions at sites 417, 484, and 501 arose together in the Beta and Gamma variants. Early studies conflicted on whether there is epistasis among these mutations with respect to ACE2 binding (6, 21, 22) . Our data demonstrate strict additivity among mutations at these three sites with respect to ACE2 binding (Figs. S3E and S5E). The co-occurrence of mutations at these three sites in SARS-CoV-2 variants may instead reflect antigenic selection for E484 and K417 (which escape different classes of neutralizing antibodies (13) , while N501Y might globally compensate for the affinity-decreasing effect of K417 mutations.

To examine the structural basis for epistatic shifts in mutational effects, we determined a crystal structure of the ACE2-bound Beta RBD (plus antibodies S304 and S309) at 2.45Å resolution (Table S1 ) and compared it to previously determined ACE2-bound Wuhan-Hu-1 and Beta structures (23, 24) . These comparisons do not reveal clear structural perturbations that explain epistatic shifts between the Wuhan-Hu-1 and Beta RBDs (Fig. S7 ). The K417N, E484K and N501Y substitutions cause minimal changes to the Beta RBD backbone ( Fig. 4A and Fig. S8A ). Furthermore, we did not detect any correlation between structural displacement of backbone or sidechain atoms in variant RBD structures and epistatic shifts in mutational effects ( Fig. 4B and Fig. S8B -E), indicating that epistatic shifts occur despite conservation of the global and local RBD structure. (Fig. S6A,B) . Labels indicate fold-decrease in geometric mean (red bar) of biological triplicate measurements. (D) Double mutant cycle illustrating positive epistasis between N501Y and Y449H. (E) Impact of epistasis on SARS-CoV-2 sequence evolution. Plot illustrates the change in a mutation's effect between Alpha (N501Y) versus Wuhan-Hu-1 deep mutational scanning data, versus the ratio in number of observed occurrences of the substitution in genomes containing N501 versus Y501 in a global SARS-CoV-2 phylogeny as of 7 February, 2022 (20) . A pseudocount was added to all substitution counts to enable ratio comparisons, and substitutions that were observed <2 times in total are excluded. Color scale reinforces the ΔΔlog10(KD) metric on the y-axis. Labeled mutations are those with |ΔΔlog10(KD)| > 0.9. Vertical line at x ~ 0.5 marks equal relative occurrence on Y501 versus N501 genomes given the larger number of substitutions that have been observed on N501 genomes to date.

To explore the cause of epistasis between Q498R and N501Y (Fig. 3A) , we examined structures of Wuhan-Hu-1 and Omicron RBDs bound to ACE2 (12, 23) complemented by molecular dynamics simulation (Fig. 4C ,D and Fig. S9 ). The Wuhan-Hu-1 structure features a stable polar contact network between ACE2 residues D38 and K353 and RBD residue Q498 (Fig. 4C) . The N501Y substitution present in Omicron disrupts this polar contact network, as the larger Y501 packs with the aliphatic base of R498 and K353, sterically blocking K353 from forming the contact bridging D38 and RBD residue 498 (Fig. 4D ). In the Omicron structure, D38 instead alternates salt bridge contacts with K353 and the substituted R498 side chain (Fig. 4D ). N501Y may therefore potentiate the affinity enhancement of Q498R by improving the energetic benefit of the stronger R498:D38 salt bridge when D38 can no longer jointly coordinate K353 in this conformation. Further support of this mechanism can be seen in the similar pattern of N501Y potentiation of Q498K (Fig. 2C) , which likewise introduces a long aliphatic side chain with a positively charged head group. The complex basis for Q498R/N501Y epistasis (Fig. 4C ,D) and the related lack of correlation between epistatic shift and structural displacement suggests that this region's mutational variability reflects a dynamic basis of ACE2 interaction.

Overall, SARS-CoV-2 has explored a diverse set of mutations during its evolution in humans. Our results show how this ongoing evolution is itself shaping potential future routes of change by shifting the effects of key mutations. Other human coronaviruses have proven adept at escaping from antibody immunity (25) because they can undergo extensive evolutionary remodeling of the amino-acid sequence of their receptor-binding domain while retaining high receptor affinity (26, 27) . Our work provides large-scale sequence-function maps that help understand how a similar process may play out for SARS-CoV-2. 

Site-saturation mutagenesis libraries spanning all 201 positions in variant RBDs were created as described for the Beta library by Greaney et al. (14) . Briefly, a plasmid encoding the Wuhan-Hu-1 RBD (Genbank MN908947, residues N331-T531) was mutagenized to create variant RBDs Alpha (N501Y), Beta (K417N+E484K+N501Y, described in (14)), Delta (L452R+T478K), and Eta (E484K). Site saturation mutant libraries in each variant background were produced by Twist Bioscience, introducing precise codon mutations to encode the 20 possible amino acids with no stop codons at each RBD position. Libraries were provided as dsDNA oligos, to which we appended N16 barcodes via PCR primer addition. Failed positions in the Twist mutagenesis were mutagenized in-house using NNS degenerate primers and pooled with the respective Twist libraries for N16 barcoding. Barcoded libraries were cloned into a recipient vector backbone for yeast-surface display (2) via Gibson Assembly. Libraries were electroporated into E. coli (NEB C3020K) and plated in duplicate at a target bottleneck of 50,000 unique barcodes per library (100,000 for Delta libraries, which were processed subsequent to the other libraries). Colonies were scraped from transformations of each RBD variant library, and plasmid was purified and transformed into the AWY101 yeast strain (28) .

As described (2, 14) , plasmid samples were sequenced using a PacBio Sequel IIe to generate long sequence reads that span the N16 barcode and RBD coding sequence. Raw CCS reads are available on the NCBI Sequence Read Archive, BioProject PRJNA770094, BioSample SAMN25941479 (together with prior Beta PacBio reads under BioSample SAMN22208699 (14)). Reads were processed using alignparse (version 0.2.4) (29) to generate a table linking each N16 barcode to its unique RBD mutant. Barcode lookup tables for each variant background are available at https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/tree/main/results/variants and https://github.com/jbloomlab/SARS-CoV-2-RBD_Delta/blob/main/results/variants/codon_variant_table.csv.

The ACE2-binding affinity of each RBD mutant was determined via massively parallel yeast-surface display titrations (2, 30) . Titrations were performed on pooled mutant libraries of the Wuhan-Hu-1, Alpha, Beta, and Eta variants, while the Delta libraries were assayed independently. For the Wuhan-Hu-1, Alpha, Beta, and Eta pools, two experimental replicate titrations were performed on the pooled "replicate 1" libraries, and a single titration was performed on the pooled "replicate 2" libraries. For the Delta library, a single experimental replicate was performed with each library replicate. Frozen yeast libraries were thawed, grown overnight in SD-CAA media (6.7 g/L Yeast Nitrogen Base, 5.0 g/L Casamino acids, 2.13 g/L MES, and 2% w/v dextrose), and backdiluted to 0.67 OD600 in SG-CAA+0.1%D (SD-CAA with 2% galactose + 0.1% dextrose replacing the 2% dextrose) to induce RBD surface expression, which proceeded for 16-18 hours at room temperature with mild agitation.

Induced cells were washed with PBS-BSA (0.2 mg/L), and split into incubations with biotinylated monomeric human ACE2 protein (ACROBiosystems AC2-H82E8) across a concentration range from 10 -6 to 10 -13 M at 1-log intervals, plus a 0 M ACE2 sample. Incubations equilibrated overnight at room temperature with mixing. Yeast were washed with ice-cold PBS-BSA and fluorescently labeled with 1:100 FITC-conjugated chicken anti-Myc (Immunology Consultants CMYC-45F) to detect yeast-displayed RBD protein and 1:200 PE-conjugated streptavidin (Thermo Fisher S866) to detect bound ACE2. At each ACE2 sample concentration, single RBD + cells were partitioned into bins of ACE2 binding (PE fluorescence) using a BD FACS Aria II as shown in Fig. S1A . A minimum of 10 million cells were collected at each sample concentration. Cells in each bin were grown overnight in 1 mL SD-CAA+pen-strep, and plasmid was isolated using 96-well yeast miniprep kits (Zymo D2005) according to manufacturer instructions, with the addition of an extended (>2 hr) Zymolyase treatment and a -80°C freeze/thaw cycle prior to cell lysis. N16 barcodes in each post-sort sample were PCR amplified as described in Starr et al. (2) and submitted for Illumina HiSeq 50bp single end sequencing. Sequencing reads are available on the NCBI Sequence Read Archive, BioProject PRJNA770094, BioSample SAMN25944367.

Demultiplexed Illumina barcode reads were aligned to library barcodes in barcode-mutant lookup tables using dms_variants (version 0.8.9), yielding a table of counts of each barcode in each FACS bin which is available at https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/counts/variant_counts.csv. Read counts in each FACS bin were downweighted by the ratio of total sequence reads from a bin to the number of cells that were sorted into that bin from the FACS log.

We estimated the level of ACE2 binding of each barcoded mutant at each ACE2 sample concentration based on its distribution of counts across FACS bins as the simple mean bin (31) as described in (2). We determined the binding constant KD describing the affinity of each barcoded mutant for ACE2 along with free parameters a (titration response range) and b (titration curve baseline) via nonlinear least-squares regression using the standard noncooperative Hill equation relating the mean sort bin to the ACE2 labeling concentration:

The measured mean bin value at a given ACE2 concentration was excluded from curve fitting for a barcode if fewer than 2 counts were observed across the four FACS bins at that ACE2 concentration. Individual concentration points were also excluded from the curve fit if they exhibited bimodality (>40% of counts of a barcode were found in two non-consecutive bins). To avoid errant fits, we constrained the baseline fit parameter b to be between 1 and 1.5, the response parameter a between 2 and 3, and the KD parameter between 1e-15 and 1e-5. The fit for a barcoded mutant was discarded if the average count across all sample concentrations was below 2, or if more than one sample concentration was missing or excluded. We also discarded curve fits where the normalized mean square residual (residuals normalized relative to the fit response parameter a) was >40 times the median normalized mean square residual across all titration fits. Final KD binding constants were expressed as -log10(KD), where higher values indicate higher binding affinity. The computational pipeline for computing per-barcode binding constants is available at https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/summary/compute_binding_Kd.md.

Because most mutants in the library were independently associated with more than one N16 barcode, we were able to average across internal replicates to derive final mutant affinities. Barcode affinities associated with identical RBD genotypes were first averaged within each experimental replicate. The correlations in per-replicate collapsed affinities are shown in Fig. S1C . The final average was then determined as the average of each replicate value. The final collapsed KD for each mutant is given in Data S1 and https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/final_variant_scores/final_variant_scores.csv. The median mutant's ACE2 binding affinity measurement collapses 15 total barcodes across the replicate titration experiments (Fig. S1E ). The number of independent barcodes collapsed into each mutation's final KD is reported in the raw data table linked above.

Libraries were grown and induced for RBD expression as described above. Induced cells were washed, labeled with 1:100 FITC-conjugated chicken anti-Myc, and washed in preparation for FACS. Single cells were partitioned into bins of RBD expression (FITC fluorescence) using a BD FACS Aria II as shown in Fig. S1B . A total of >10 million viable cells (estimated by plating of post-sort dilutions) were collected for each library. Cells in each bin were grown out, plasmid isolated, and N16 barcodes sequenced as described above, except read count downweighting used the post-sort colony counts instead of the FACS log counts. Sequencing reads are available on the NCBI Sequence Read Archive, BioProject PRJNA770094, BioSample SAMN25944367.

We estimated the level of RBD expression (mean fluorescence intensity, MFI) of each barcoded mutant based on its distribution of counts across FACS bins and the known log-transformed fluorescence boundaries of each sort bin using a maximum likelihood approach (2, 31) , implemented using the fitdistrplus package (version 1.0.14) in R (32) . Expression measurements were discarded for barcodes for which fewer than 10 counts were observed across the four FACS bins. The full pipeline for computing per-barcode expression values is available at https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/summary/compute_expression_meanF.md. Final mutant expression values were collapsed within and across replicates as described above (correlation between replicates shown in Fig. S1D) , with a median of 10 barcodes collapsed into each mutant expression measurement (Fig. S1E) . Final mutant expression values are available in Data S1 and https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/final_variant_scores/final_variant_scores.csv.

Epistatic shifts at each site between pairs of RBD variants were quantified via a summary metric, Jensen-Shannon divergence, that captures variation in the 20 amino-acid-level affinity or expression phenotypes measured at a position (33) . First, affinity (dissociation constant KD) or expression (MFI) phenotypes fi of each mutant i at a site were transformed to a probability analog πi:

Note that for affinity, the resulting πi values correspond to Boltzmann weights, since -ln(KD) is proportional to the free energy in units of kBT. The Jensen-Shannon divergence between vectors p and q representing the 20 amino acid πi at a site in two RBD variants is the average Kullback-Leibler divergence of p and q from their per-index-mean vector m:

where the Kullback-Leibler divergence is calculated as:

The Jensen-Shannon divergence ranges from 0 for two vectors of probabilities that are identical to 1 for two vectors that are completely dissimilar. For context, scatterplots in Fig. 2C and Figs. S3, S4C illustrate the amino-acid-level epistatic perturbations that give rise to a range of Jensen-Shannon divergence values. To avoid noisier measurements artifactually inflating the epistatic shift metric, a given amino acid mutation was only included in the comparison between a pair of RBD variants if its final measurement was averaged across 3 or more individual barcodes in each RBD background. The calculation of epistatic shifts can be found at https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS_variants/blob/main/results/summary/epistatic_shifts.md. For epistatic interactions between particular mutations (e.g., Fig. 3A ,B,D and Fig. S5D ,E), the expected difference in binding of a multiply mutated genotype compared to wildtype in the absence of epistasis is the sum of the Δlog10(KD) measurements of the component single mutations. Any deviation from this addition is a reflection of epistasis. An observed phenotype that is higher than the expected additive phenotype is considered "positive" epistasis, while an observed phenotype that is lower than the additive expectation is considered "negative" epistasis.

A real-time phylogenetic tree of global SARS-CoV-2 genomes was used to count substitution accrual on internal branches of the SARS-CoV-2 phylogeny. The SARS-CoV-2 mutation-annotated tree described by McBroome et al. (20) was downloaded on Feb. 7, 2022. Nucleotide mutations annotated on the tree were converted to amino acid mutations using matUtils (version 0.4.8) (20) , using the Wuhan-Hu-1 genome (NCBI RefSeq NC_045512.2) as a reference. Amino acid substitutions were tabulated, excluding substitutions that occurred to isolated terminal branches. Substitutions were counted as occurring on N501 versus Y501 genomes, and substitutions that occurred coincidental with a 501 substitution were counted as accruing on the derived 501 state from that branch. A pseudocount of 1 was added to all substitution counts to enable log-ratio comparison of mutation accrual on N501 versus Y501 genomes (Fig. 3E) .

A spike-pseudotyped lentiviral platform (34) was used to measure entry efficiency and antibody neutralization of spike variants. Single and double amino acid mutations and the entire suite of mutations found in Omicron BA.1 (8) were introduced into a previously described spike-expression plasmid containing D614G and a 21-amino-acid deletion in the cytoplasmic tail (Addgene 158762) (34) . Plasmids were purified in triplicate for independent viral rescues from separate plasmid stocks.

Spike pseudotyped lentiviral particles were produced in HEK-293T cells (ATCC CRL-3216). 5e5 cells per well were seeded in 6-well plates in 2mL D10 growth media (Dulbecco's Modified Eagle Medium with 10% heatinactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin) at 37℃ in a humidified 5% CO2 incubator. 24 hours later, cells were transfected using BioT (Bioland Scientific) with 340 ng of spike expression plasmid (or no spike control), 1,135 ng of a Luciferase_IRES_ZsGreen lentiviral backbone, and 865 ng of Gag/Pol lentiviral helper plasmid (BEI Resources NR-52517). Media was changed 24 hours post-transfection. Approximately 65 hours post-transfection, viral supernatants were collected, filtered through a 0.45 μm syringe filter, and stored at -80°C. Particle concentration of each viral supernatant was determined in technical duplicate by p24 ELISA (Advanced Bioscience Laboratories Cat. # 5421) versus a known particle standard according to manufacturer instructions.

Entry titers of spike-pseudotyped lentiviral particles were determined on HEK-293T cell lines expressing high levels of human ACE2 (BEI Resources NR-52511) (34) and low levels of human ACE2. The low level ACE2 cells were created by genomically integrating single AttB_ACE2-miRFP670_IRES_mCherry-H2A-P2A-PuroR plasmids into HEK-293T LLP-Int-BFP-IRES-iCasp9-Blast Bxb1 landing pad cells (35) , followed by selection with 1 μg/mL puromycin. Low ACE2 levels were achieved by using a "AATTTT[ATG]" Kozak sequence preceding ACE2 to decrease its steady-state abundance, unmasking entry deficits (35) . All cells were grown in D10 media, and the ACE2low cell line was supplemented with 1 μg/mL doxycycline to maintain ACE2 expression. To quantify ACE2 expression levels, HEK-293T cells expressing high, low or no ACE2 were resuspended in FACS buffer (PBS+2% BSA) and incubated for 1 h with 1:500 rabbit anti-ACE2 antibody (Abcam ab272500). Cells were washed with FACS buffer and labeled for 1 h with 1:3000 Alexa-Fluor-488 goat anti-rabbit IgG H&L (Abcam ab150077). Cells were washed with FACS buffer and fixed with 4% PFA. ACE2 expression (AF488 fluorescence) was measured via flow cytometry on a BD LSRFortesssa X50, and geometric mean fluorescence intensity was compared between samples (Fig. S6A) .

For titering, ACE2-high and ACE2-low cells were seeded at 1.2e4 cells per well in poly-L-lysine-coated 96well plates (Greiner 655930) in 50 uL D10 media (plus 1 μg/mL doxycycline for the ACE2-low cell line). 24 hours later, 100 μL of viral supernatants prepared across a 2-fold dilution series (1:2 to 1:256) were added to cells. Approximately 65 hours post-infection, luciferase activity was measured (Promega Bright-Glo, E2620). Relative luciferase unit (RLU) measures were averaged across viral dilutions within linear range and expressed relative to p24 particle concentration as the final p24-normalized entry titer (RLU/pg p24).

Antibody neutralization of spike-pseudotyped particles was measured on ACE2-high cell lines in technical duplicate. Cells were seeded in 96-well plates as described above for virus titering. 24 hours later, viral supernatants were diluted to a to a target of 400,000 RLU per well, and incubated for 1 hour at 37°C with monoclonal antibody across 8 four-fold dilution points starting at a concentration 400-fold higher than the expected IC50 (16) . 100 μL of antibody-virus mixture was added to cells, and luciferase activity was measured ~65 hours post-infection as described for titering experiments. Fraction infectivity of each sample was calculated relative to a no-antibody well inoculated with the same viral supernatant in a matched row of the 96-well plate. We used neutcurve (https://jbloomlab.github.io/neutcurve, version 0.5.7) to calculate the inhibitory concentration 50% (IC50) of each antibody against each virus by fitting a Hill curve with fixed baseline 0 and plateau 1.

SARS-CoV-2 Beta RBD for crystallization (residues 328-531 of S protein from GenBank NC_045512.2 with N-terminal signal peptide and C-terminal 8xHis-tag) was expressed in Expi293F (Thermo Fisher Scientific) cells in the presence of 10 µM kifunensine at 37°C and 8% CO2. Transfection was performed using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific). Cell culture supernatant was collected four days after transfection and supplemented with 10x PBS to a final concentration of 2.5x PBS (342.5 mM NaCl, 6.75 mM KCl and 29.75 mM phosphates). SARS-CoV-2 Beta RBD was purified using a 5 mL HisTalon Superflow cartridge (Takara Bio) followed by buffer exchange into PBS using a HiPrep 26/10 desalting column (Cytiva).

Human ACE2 for crystallization (residues 19-615 from Uniprot Q9BYF1 with a C-terminal thrombin cleavage site-TwinStrep-10xHis-GGG-tag, and N-terminal signal peptide) was expressed in Expi293F cells in the presence of 10 µM kifunensine at 37°C and 8% CO2. Transfection was performed using the Expi293 transfection kit (Thermo Fisher Scientific). Cell culture supernatant was collected five days after transfection and supplemented to a final concentration of 80 mM Tris-HCl pH 8.0, 100 mM NaCl, and then incubated with BioLock (IBA GmbH) solution. ACE2 was purified using a 1 mL StrepTrap HP column (Cytiva). Protein-containing fractions were pooled and digested with EndoH and thrombin at 4°C overnight. ACE2 was further purified by size exclusion chromatography using a Superdex 200 Increase 10/300 GL column (Cytiva) equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl.

SARS-CoV-2 Beta RBD was mixed with a 1.4-fold molar excess hACE2, and a 1. 

Coordinates of the Wuhan-Hu-1 RBD:hACE2 structure were prepared as previously described (42) , where the RBD was taken from PDB 6M0J, hACE2 from PDB 1R42, and their complex generated by aligning the proteins to the CST 6M0J structure. Complex glycans were then added to the structure at positions 53, 90, 103, 322, 432, 546, and 690 on hACE2 and 343 on the RBD followed by refinement with ISOLDE (39). These coordinates were then prepared using QuickPrep (MOE v2020.0901, https://www.chemcomp.com). The Omicron RBD:hACE2:S304:S309 structure from PDB 7TN0 was glycosylated as described above and prepared using QuickPrep.

The coordinates of each RBD:ACE2 complex were parameterized using tleap (43) . The following force fields were used: Amber ff14SB for the protein (44), GLYCAM_06j-1 for glycans (45) , TIP3P for water (46) and for the neutralizing 0.15 M of NaCl Joung & Cheatham parameters (47) were used, and the Li parameters (48) for Zn and divalent ions.

For each complex, a nine-stage restrained minimization and equilibration protocol was used as previously described (49) using Amber20 (43) . Initial minimization involved 10,000 steps and positional restraints applied to all heavy atoms resolved in the crystal structures with a 100 kcal/molÅ 2 force constant. 8 independent simulations were initialized using different initial velocities drawn randomly from the Maxwell-Boltzmann distribution, in an NVT ensemble, gentle heating from 100 K to 300 K over 100 ps, and positional restraints on all heavy atoms with a 100 kcal/molÅ 2 force constant. Next the ensemble was switched to NPT, a constant temperature of 300 K over 100 ps, and positional restraints on all heavy atoms with a 100 kcal/molÅ 2 force constant. Next, a 250 ps stage was run in NPT at 300 K with positional restraints on all heavy atoms with a 10 kcal/molÅ 2 force constant. Next minimization for 10,000 steps was performed with positional restraints on backbone atoms with a 10 kcal/molÅ 2 force constant. This was followed by 100 ps of NPT at 300 K with positional restraints on backbone atoms with a 10 kcal/molÅ 2 force constant. Next 100 ps of NPT at 300 K with positional restraints on backbone atoms with a 1.0 kcal/molÅ 2 force constant. Next 100 ps of NPT at 300 K with positional restraints on backbone atoms with a 0.1 kcal/molÅ 2 force constant. The final stage of equilibration was 2.5 ns of unrestrained MD in NPT at 300 K for each of the 8 independent trajectories for each complex. The 8 pairs of simulations were extended for 700 ns each in NPT at 300 K. Snapshots were saved every 1 ns for post-processing. 5.6 μs of aggregated MD simulations were obtained for Omicron RBD:hACE2:S304:309 and 5.6 μs for Wuhan-Hu-1 RBD:hACE2.

Simulations were post-processed using cpptraj (50) . Coordinates were imaged, RMS-aligned using Cα atoms to the respective crystal structure coordinates, water and ions stripped and saved to netcdf files. Distances were computed using the atoms of Q (OE1, HE1/2, NE2), N (OD1, HD1/2), D (OD1 or OD2), E (OE1 or OE2), R (HE, HH11/2, HH21/2), and K (HZ1/2/3). For each residue pair (H-bond or salt bridge) all distance pairs between atoms were computed and the lowest value of those pairs used as the hydrogen bond or salt bridge distance. Figures were generated using matplotlib.

Volumetric maps were computed using the VolMap Plugin in VMD (51) 33-38.] . Default parameters were used to compute the atomic densities observed over a grid, where the width of gaussian functions centered at each grid point bore widths equal to the atomic radii in each respective residue and then weighted by the atomic mass. The double sum of these gaussians over the grid points and over the course of the simulation were used to generate an isosurface map. The isosurfaces were rendered using an occupancy threshold of 0.5.

We analyzed atomic displacements between structures of ACE2-bound variant RBDs. X-ray crystallography structures included Wuhan-Hu-1: PDB 6M0J (23); Alpha: PDB 7EKF (24); Beta: PDB 7EKG (24); and Delta: PDB 7WBQ (52). Cryo-EM structure local refinements included Wuhan-Hu-1: PDB 7KMB (53); Alpha: PDB (54); Beta: PDB 7VX4 (55); and Delta: PDB 7V8B. Structures were aligned in PyMol to minimize RBD structure RMSD. Pairwise distances between Cα or all-atom-averages (for unmutated sites) between aligned structures were computed using the bio3d package in R (56) .

Interactive visualizations available at https://jbloomlab.github.io/SARS-CoV-2-RBD_DMS_variants/ were built using altair, version 4.2 (57) . Sites of strong antibody escape ( Fig. 2A and Fig. S4A ) were those with an average normalized total escape of >0.05 across all antibodies in the aggregate tool described by (9) as of November 27, 2021 (https://raw.githubusercontent.com/jbloomlab/SARS2_RBD_Ab_escape_maps/03910f5bb6bc86ab823e9cf40f34b07b4 03f26d2/processed_data/escape_data.csv). (Fig. S1 ). The wildtype amino acid in each variant is indicated with an "x", and gray squares indicate missing mutations in each library. An interactive version of this map is at https://jbloomlab.github.io/SARS-CoV-2-RBD_DMS_variants/RBD-heatmaps/, and raw data are in Data S1. Fig. 2C . Orange letters are mutations that were sampled with fewer than 3 unique barcodes across titration replicates in the Beta and/or Wuhan-Hu-1 data and were therefore not included in the epistatic shift computation as described in Methods. Scatterplots for all sites can be visualized at https://jbloomlab.github.io/SARS-CoV-2-RBD_DMS_variants/epistatic-shifts/. Fig. 2C and Fig. S3 . These scatter plots suggest that at the shifted sites, the Beta RBD is more sensitive to mutation compared to Wuhan-Hu-1, reflected in the concave shape of each plot. This is in contrast to idiosyncratic epistatic shifts in individual mutation's effects on ACE2 binding as seen in e.g. Fig. 2C . (Fig. 3B) . Antibody escape is estimated from a calculator that aggregates >250 antibody deep mutational scanning escape profiles to determine the expected antigenic effect of mutations (9) . (C) Cumulative ACE2-binding affinity versus antibody escape of Omicron BA.1 mutations (Fig. 3B and (B) ). Antibody escape calculated as in (B), except mutations were introduced consecutively into the calculator in the order shown, which accounts for possible redundancy in escape mutations at overlapping antibody epitopes. (D) Double mutant cycle diagram illustrating negative sign epistasis between N501Y and G446V. (E) Triple mutant cycle illustrating additivity among the three mutations in the Beta RBD. See also Fig. S4E . that showed escape at site Y449 in prior deep mutational scanning data (16) . Each point is the mean and standard error from technical duplicates. S2E12 is a negative control antibody, which was not expected to be escaped by the Y449H or N501Y mutations based on prior deep mutational scanning data (16) . (E) Fold-change in neutralization of spike-pseudotyped lentivirus from the curves in (D). The Y449H/N501Y double mutant shows 2.4x and 6.3x synergistic escape from S2H13 and S2X58, respectively, compared to the multiplicative fold-change of the single mutants. Fig. 2C ). Site 403 has not previously been implicated in key events in the functional or antigenic evolution of SARS-related coronaviruses, but mutations in this region have been shown to transmit allosterically to distal regions of the ACE2-binding surface (58, 59) , which may be further reflected in many epistatic shifts in mutation effects on RBD expression in this region (Fig. S4) . Backbone structure alignment between ACE2-bound RBD X-ray crystal structures (left; Wuhan-Hu-1 (PDB 6M0J, 2.45Å resolution), Alpha (7EKF, 2.85Å), Beta (7EKG, 2.63Å), and Delta (7WBQ, 3.34Å)) or local refinement maps from ACE2-bound spike cryo-EM structures (right; Wuhan-Hu-1 (PDB 7KMB, 3.39Å resolution), Alpha (7MJN, 3.29Å), Beta (7VX4, 3.90Å) and Delta (7V8B, 3.2Å)). (B-E) Changes in backbone and sidechain properties in variant versus Wuhan-Hu-1 structures. For each property, the left hand plot shows the value for each variant RBD versus Wuhan-Hu-1 as a lineplot across RBD sites; sites with the largest displacements in the Beta structures are labeled. Right Hand plot shows relationship across RBD sites between the property and epistatic shift from deep mutational scanning ( Fig. 2A) . Calculated properties include the mainchain Cα displacement from X-ray (B) or cryoEM (D) structures, and all-atom average displacement from X-ray (C) or cryoEM (E) structures. 

The biological and clinical significance of emerging SARS-CoV-2 variants

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission

Epistasis in protein evolution

ACE2 binding is an ancestral and evolvable trait of sarbecoviruses

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution

In vitro evolution predicts emerging CoV-2 mutations with high affinity for ACE2 and cross-species binding

An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Genotype to Phenotype Japan (GP-Japan) Consortium members

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals

Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein

A daily-updated database and tools for comprehensive SARS-CoV-2 mutation-annotated trees

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants

A human coronavirus evolves antigenically to escape antibody immunity. bioRxiv (2020)

Receptor-binding loops in alphacoronavirus adaptation and evolution

The human coronavirus HCoV-229E S-protein structure and receptor binding

A novel high-throughput screen reveals yeast genes that increase secretion of heterologous proteins

alignparse: A Python package for parsing complex features from high-throughput long-read sequencing

Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves

Sort-seq under the hood: implications of design choices on large-scale characterization of sequencefunction relations

fitdistrplus: An R Package for Fitting Distributions

Site-Specific Amino Acid Preferences Are Mostly Conserved in Two Closely Related Protein Homologs

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection

Phaser crystallographic software

Features and development of coot

ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps

REFMAC5 for the refinement of macromolecular crystal structures

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB

GLYCAM06: a generalizable biomolecular force field. Carbohydrates

Comparison of simple potential functions for simulating liquid water

Cheatham 3rd, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations

Systematic parameterization of monovalent ions employing the nonbonded model

A human transcription factor in search mode

Cheatham 3rd, Parallelization of CPPTRAJ enables large scale analysis of molecular dynamics trajectory data

VMD: Visual molecular dynamics

Receptor binding and complex structures of human ACE2 to spike RBD from Omicron and Delta SARS-CoV-2

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM

Bio3d: an R package for the comparative analysis of protein structures

Altair: Interactive Statistical Visualizations for Python

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

We thank the Genomics and Flow Cytometry core facilities at Fred Hutchinson Cancer Research Center,